The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus

The first human glucagon-like peptide-1 analog (liraglutide) was registered in Russia in May 2010. This review contains data on the results of randomizedclinical studies of this preparation applied to the treatment of patients with DM2 as monotherapy and in combination with traditional hypoglycemica...

Full description

Bibliographic Details
Published in:	Сахарный диабет
Main Author:	Marina Vladimirovna Shestakova
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2010-09-01
Subjects:	incretins human glucagon-like peptide-1 (glp-1) liraglutide victoza
Online Access:	https://www.dia-endojournals.ru/jour/article/view/5497

Similar Items

Glucagon-like peptide-1 analogues: An overview
by: Vishal Gupta
Published: (2013-01-01)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
by: Campbell RK, et al.
Published: (2010-07-01)

Incretins role in Latent autoimmune diabetes of adults pathogenesis, the possibility of therapy with combination of glucagon-like peptide-1 agonist (GLP-1) and insulin.
by: Iuliia V. Silko, et al.
Published: (2016-07-01)

Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
by: Syed Faizan Mehdi, et al.
Published: (2023-05-01)

Glucagon Like Peptide 1 and Evidence Around Diabetes Specific Nutrition
by: ANSHU JOSHI, et al.
Published: (2019-06-01)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01)

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review
by: Khang Duy Ricky Le, et al.
Published: (2024-01-01)

Glucagon-like Peptide-1 Receptor Agonists: Are They as Good as They Seem? A Systematic Review of Severe Adverse Effects
by: Pranjal Sharma, et al.
Published: (2024-08-01)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)

GLP-1 Analog Liraglutide Improves Vascular Function in Polymicrobial Sepsis by Reduction of Oxidative Stress and Inflammation
by: Johanna Helmstädter, et al.
Published: (2021-07-01)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01)

The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
by: Anja Harej Hrkać, et al.
Published: (2024-10-01)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
by: Nina A. Petunina, et al.
Published: (2018-09-01)

Effects of exercise on glucagon-like peptide-1 (GLP-1)
by: Shin-ya Ueda, et al.
Published: (2013-06-01)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
by: A. Delgado, et al.
Published: (2021-04-01)

Liraglutide; A New Hope for Obese Diabetics
by: Ajeet Kumar, et al.
Published: (2020-12-01)

Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon
by: Keizo Kanasaki, et al.
Published: (2019-05-01)

Renal effects of glucagon-like peptide receptor agonists in patients with type 1 diabetes mellitus
by: O K Vikulova, et al.
Published: (2018-06-01)

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
by: C. Meurot, et al.
Published: (2022-01-01)

Efficacy and Safety of Glucagon Like Peptide-1 Receptor Agonism Based Therapies in Obstructive Sleep Apnoea: A Systematic Review and Meta-Analysis
by: Deep Dutta, et al.
Published: (2025-01-01)

Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
by: Joon Seok Park, et al.
Published: (2025-05-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males
by: Dorte B. Zilstorff, et al.
Published: (2024-03-01)

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
by: Alorfi NM, et al.
Published: (2022-08-01)

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-05-01)

Obezitenin Medikal Tedavisinde Liraglutide Etkinliğinin Araştırılması
by: Murat Kose, et al.
Published: (2023-09-01)

Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration
by: Katherine O. Kopp, et al.
Published: (2024-07-01)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
by: Knop FK, et al.
Published: (2010-05-01)

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)

Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity
by: Tatiana I. Romantsova
Published: (2018-04-01)

Glucagon-Like Peptide-1 Receptor Regulates Macrophage Migration in Monosodium Urate-Induced Peritoneal Inflammation
by: Jun Chen, et al.
Published: (2022-01-01)

Role of FFAR3 in ketone body regulated glucagon-like peptide 1 secretion
by: Sara MT. Persson, et al.
Published: (2024-09-01)

Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms
by: Bruno Vergès, et al.
Published: (2022-11-01)

Corrigendum: Glucagon-Like Peptide-1 Receptor Regulates Macrophage Migration in Monosodium Urate-Induced Peritoneal Inflammation
by: Jun Chen, et al.
Published: (2022-03-01)

Commentary on “Electroacupuncture Inhibited Spinal Glial Activation in Neuropathic Pain via Glucagon-like Peptide 1/Glucagon-like Peptide 1 Receptor Signaling”
by: Hulya Karatas
Published: (2024-09-01)

A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait
by: Saleh Alali, et al.
Published: (2025-05-01)

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus
by: E A Shestakova, et al.
Published: (2014-10-01)

The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
by: Jonathan D. Douros, et al.
Published: (2025-02-01)

Glucagon‐like peptide agonists: A prospective review
by: Zamara Mariam, et al.
Published: (2024-01-01)

Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight
by: Claire H. Feetham, et al.
Published: (2025-09-01)